Northwestern Medicine scientists have discovered that targeting neuronal signaling controlling aberrant learning in the ...

Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone -- Topline Results ...

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...

Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring, reported that its drug for Parkinson’s disease improved motor symptom control as an add-on therapy in a late-stage trial. The ...

Explore off times in advanced Parkinson's disease, understand symptoms, communicate with your doctor, and consider treatment strategies and lifestyle adjustments.

A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness, coordination, ...

Researchers at McGill University have uncovered a surprising twist in how dopamine affects movement, overturning a ...